NASDAQ:TMDX

TransMedics Group Stock Forecast, Price & News

$28.61

+0.30 (+1.06 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$28.20

▼

$29.12

50-Day Range

$21.63

▼

$34.52

52-Week Range

$11.51

▼

$49.50

Volume257,555 shs

Average Volume657,696 shs

Market Capitalization$790.32 million

P/E RatioN/A

Dividend YieldN/A

Beta1.99

30 days | 90 days | 365 days | Advanced Chart

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
June 10, 2021 | finance.yahoo.com

TransMedics Group (NASDAQ:TMDX) Shares Gap Up to $26.43
June 9, 2021 | americanbankingnews.com

TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021)
June 8, 2021 | finance.yahoo.com

Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2021 Update
June 5, 2021 | seekingalpha.com

TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of "Buy" from Brokerages
June 4, 2021 | americanbankingnews.com

TransMedics Group (NASDAQ:TMDX) Stock Price Up 5.1%
May 21, 2021 | americanbankingnews.com

Earnings Update: TransMedics Group, Inc. (NASDAQ:TMDX) Just Reported And Analysts Are Trimming Their Forecasts
May 7, 2021 | nasdaq.com

Transmedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q1 2021 Results - Earnings Call Transcript
May 6, 2021 | seekingalpha.com

TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
May 4, 2021 | finance.yahoo.com

1 Feel-Good Healthcare Stock That Could Turn Your Tax Return Into Riches
April 22, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TMDX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.transmedics.com
Phone978-552-0900
Employees110
Year FoundedN/A

Sales & Book Value

Annual Sales$25.64 million
Price / Sales30.82
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.83 per share
Price / Book7.47

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-28,750,000.00
Net Margins-110.54%
Return on Equity-26.18%
Return on Assets-17.94%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares27,624,000
Market Cap$790.32 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.58 out of 5 stars

Medical Sector

460th out of 2,100 stocks

Electromedical Equipment Industry

9th out of 62 stocks

3.3 Analyst's Opinion

Consensus Rating
TransMedics Group has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.60, TransMedics Group has a forecasted upside of 52.4% from its current price of $28.61.
Amount of Analyst Coverage
TransMedics Group has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
TransMedics Group has received 59 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TransMedics Group has received 71 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TransMedics Group has received 54.62% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote “Outperform” if you believe TMDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TransMedics Group does not currently pay a dividend.
Dividend Growth
TransMedics Group does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,559,844.00 in company stock.
Percentage Held by Insiders
Only 10.30% of the stock of TransMedics Group is held by insiders.
Percentage Held by Institutions
67.47% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for TransMedics Group are expected to grow in the coming year, from ($0.92) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TransMedics Group is -26.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TransMedics Group is -26.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TransMedics Group has a P/B Ratio of 7.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

Is TransMedics Group a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group or view top-rated stocks.

What stocks does MarketBeat like better than TransMedics Group?

Wall Street analysts have given TransMedics Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TransMedics Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TransMedics Group?

TransMedics Group saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,260,000 shares, an increase of 23.5% from the May 13th total of 1,020,000 shares. Based on an average daily volume of 590,300 shares, the short-interest ratio is currently 2.1 days. Approximately 5.1% of the shares of the company are sold short.
View TransMedics Group's Short Interest.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for TransMedics Group.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) issued its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.01. TransMedics Group had a negative net margin of 110.54% and a negative trailing twelve-month return on equity of 26.18%.
View TransMedics Group's earnings history.

How has TransMedics Group's stock price been impacted by Coronavirus?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TMDX stock has increased by 110.1% and is now trading at $28.61.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TMDX?

5 brokers have issued 12-month target prices for TransMedics Group's shares. Their forecasts range from $15.00 to $79.00. On average, they expect TransMedics Group's stock price to reach $43.60 in the next year. This suggests a possible upside of 52.4% from the stock's current price.
View analysts' price targets for TransMedics Group or view top-rated stocks among Wall Street analysts.

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:

Dr. Waleed H. Hassanein, Founder, MD, CEO, Pres & Director (Age 53, Pay $939.73k)
Mr. Stephen Gordon, CFO. Treasurer & Sec. (Age 53, Pay $512.34k)
Dr. Tamer I. Khayal, Chief Commercial Officer (Age 52, Pay $533.69k)
Mr. John F. Carey, VP of Operations (Age 56)
Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 50)
Mr. Mark Anderson, Sr. Director of Technology Devel.
Ms. Susan Goodman, VP of HR

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

Who are some of TransMedics Group's key competitors?

Some companies that are related to TransMedics Group include InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), ViewRay (VRAY), AxoGen (AXGN), Cutera (CUTR), Semler Scientific (SMLR), Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP), Second Sight Medical Products (EYES), Movano (MOVE), BioSig Technologies (BSGM) and IRIDEX (IRIX).
View all of TMDX's competitors.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and The Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.89%), Credit Suisse AG (5.44%), Sandhill Capital Partners LLC (4.33%), KPCB XIII Associates LLC (3.34%), Bellevue Group AG (2.69%) and Federated Hermes Inc. (2.19%). Company insiders that own TransMedics Group stock include Abrams Capital Management, LP, David Weill, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends for TransMedics Group.

Which major investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Zimmer Partners LP, Emerald Advisers LLC, Sandhill Capital Partners LLC, Northern Trust Corp, JPMorgan Chase & Co., Taylor Wealth Management Partners, KPCB XIII Associates LLC, and Squarepoint Ops LLC. Company insiders that have sold TransMedics Group company stock in the last year include Abrams Capital Management, LP, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, and Waleed H Hassanein.
View insider buying and selling activity for TransMedics Group or view top insider-selling stocks.

Which major investors are buying TransMedics Group stock?

TMDX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., Stephens Inc. AR, Dimensional Fund Advisors LP, Voloridge Investment Management LLC, Bellevue Group AG, Morgan Stanley, and Nuveen Asset Management LLC.
View insider buying and selling activity for TransMedics Group or or view top insider-buying stocks.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $28.61.

How much money does TransMedics Group make?

TransMedics Group has a market capitalization of $790.32 million and generates $25.64 million in revenue each year. The company earns $-28,750,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does TransMedics Group have?

TransMedics Group employs 110 workers across the globe.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

Where are TransMedics Group's headquarters?

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here